Introduction: The Health Technology Assessment report on effectiveness, cost-effectiveness and appropriateness of homeopathy was compiled on behalf of the Swiss Federal Office for Public Health (BAG) within the framework of the ‘Program of Evaluation of Complementary Medicine (PEK)’. Materials and Methods: Databases accessible by Internet were systematically searched, complemented by manual search and contacts with experts, and evaluated according to internal and external validity criteria. Results: Many high-quality investigations of pre-clinical basic research proved homeopathic high-potencies inducing regulative and specific changes in cells or living organisms. 20 of 22 systematic reviews detected at least a trend in favor of homeopathy. In our estimation 5 studies yielded results indicating clear evidence for homeopathic therapy. The evaluation of 29 studies in the domain ‘Upper Respiratory Tract Infections/Allergic Reactions’ showed a positive overall result in favor of homeopathy. 6 out of 7 controlled studies were at least equivalent to conventional medical interventions. 8 out of 16 placebocontrolled studies were significant in favor of homeopathy. Swiss regulations grant a high degree of safety due to product and training requirements for homeopathic physicians. Applied properly, classical homeopathy has few side-effects and the use of high-potencies is free of toxic effects. A general health-economic statement about homeopathy cannot be made from the available data. Conclusion: Taking internal and external validity criteria into account, effectiveness of homeopathy can be supported by clinical evidence and professional and adequate application be regarded as safe. Reliable statements of cost-effectiveness are not available at the moment. External and model validity will have to be taken more strongly into consideration in future studies.

Modic type 1 changes (MC1) are painful vertebral bone marrow lesions frequently found in patients suffering from chronic low-back pain. Marrow fibrosis is a hallmark of MC1. Bone marrow stromal cells (BMSCs) are key players in other fibrotic bone marrow pathologies, yet their role in MC1 is unknown. The present study aimed to characterise MC1 BMSCs and hypothesised a pro-fibrotic role of BMSCs in MC1. BMSCs were isolated from patients undergoing lumbar spinal fusion from MC1 and adjacent control vertebrae. Frequency of colony-forming unit fibroblast (CFU-F), expression of stem cell surface markers, differentiation capacity, transcriptome, matrix adhesion, cell contractility as well as expression of pro-collagen type I alpha 1, α-smooth muscle actin, integrins and focal adhesion kinase (FAK) were compared. More CFU-F and increased expression of C-X-C-motif-chemokine 12 were found in MC1 BMSCs, possibly indicating overrepresentation of a perisinusoidal BMSC population. RNA sequencing analysis showed enrichment in extracellular matrix proteins and fibrosis-related signalling genes. Increases in pro-collagen type I alpha 1 expression, cell adhesion, cell contractility and phosphorylation of FAK provided further evidence for their pro-fibrotic phenotype. Moreover, a leptin receptor high expressing (LEPRhigh) BMSC population was identified that differentiated under transforming growth factor beta 1 stimulation into myofibroblasts in MC1 but not in control BMSCs. In conclusion, pro-fibrotic changes in MC1 BMSCs and a LEPRhigh MC1 BMSC subpopulation susceptible to myofibroblast differentiation were found. Fibrosis is a hallmark of MC1 and a potential therapeutic target. A causal link between the pro-fibrotic phenotype and clinical characteristics needs to be demonstrated.

This study examined a large dataset of ultra-cycling race results to investigate the sex difference in ultra-cycling performance (100 to 500 miles) according to age and race distance. Data from the time period 1996-2018 were obtained from online available database of the ultra-cycling marathon association (UMCA), including distance-limited ultra-cycling races (100, 200, 400, and 500 miles). A total of 12,716 race results were analyzed to compare the performance between men and women by calendar year, age group (18-34, 35-44, 45-59, and 60+ years), and race distance. Men were faster than women in 100 and 200 mile races, but no sex differences were identified for the 400 and 500 mile races. The performance ratio (average cycling speed men /average cycling speed women ) was smaller in the 200 mile races compared to the 100 mile races and remained stable in the 400 and 500 mile races. In all race distances, the difference in average cycling speed between women and men decreased with increasing age. The gender gap in performance was closed in several distance-limited ultra-cycling races, such as the 400 and 500 mile races.

BackgroundChanges in single skinfold thickness and body fat have been investigated in ultraswimmers and ultracyclists, but not in ultrarunners. The present study investigated the changes in single skinfold thickness during a 100 km ultramarathon.MethodsFirstly, we investigated associations between prerace preparation and prerace body composition and, secondly, changes in single skinfold thickness during a 100 km ultramarathon in 219 male ultramarathoners. Changes in fat mass and skeletal muscle were estimated using anthropometric methods.ResultsKilometers run weekly prerace and running speed during training were negatively associated with all skinfold thicknesses (P < 0.05) except for the front thigh skinfold. During the race, skinfold thickness at the pectoral (−0.1%), suprailiac (−1.8%), and calf (−0.8%) sites decreased (P < 0.05). The subjects lost 1.9 ± 1.4 kg of body mass (P < 0.001), 0.7 ± 1.0 kg of estimated skeletal muscle mass (P < 0.001), and 0.2 ± 1.3 kg of estimated fat mass (P < 0.05). The decrease in body mass was positively related to the decrease in both estimated skeletal muscle mass (r = 0.21, P = 0.0017) and estimated fat mass (r = 0.41, P < 0.0001).ConclusionFirstly, prerace fat mass and prerace skinfold thickness were associated with both volume and speed in running training. Secondly, during the ultramarathon, skinfold thickness decreased at the pectoral, suprailiac, and calf sites, but not at the thigh site. Percent decreases in skinfold thickness for ultrarunners was lower than the percent decreases in skinfold thickness reported for ultraswimmers and ultracyclists.